Overview

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2026-04-17

Target enrollment:

Participant gender:

Summary

This is a phase 2 clinical study,to explore the efficacy and safety of Disitamab Vedotin in patients with locally advanced or metastatic pancreatic cancer expressing HER2.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

disitamab vedotin
Gemcitabine